National Trauma Research Institute, Melbourne, Victoria; Department of Neurosurgery, Royal Melbourne Hospital, Parkville, Victoria; Department of Neurosurgery, The Alfred Hospital, Melbourne, Victoria.
Department of Neurosurgery, The Alfred Hospital, Melbourne, Victoria; Central Clinical School, Faculty of Medicine, Nursing and Health Sciences, Monash University, Melbourne, Victoria, Australia.
World Neurosurg. 2021 Jan;145:229-240. doi: 10.1016/j.wneu.2020.09.044. Epub 2020 Sep 16.
The survival outcomes of clear cell ependymomas are poorly understood. This study clarifies the role of surgery and adjuvant therapy when this morphologically distinct tumor is encountered.
A systematic search for studies relating to clear cell ependymomas was conducted. Primary outcomes were progression-free survival and overall survival. Prognostic variables were age, sex, tumor consistency, extent of resection, and postoperative adjuvant therapy. Kaplan-Meier survival curves were generated and compared by the log-rank test. Multivariate Cox regression models were constructed, interrogated with Schoenfeld residuals, and used to identify independent prognostic factors.
Of the 384 articles retrieved, 8 articles comprising 77 cases of clear cell ependymoma were included. Five-year overall survival and progression-free survival were 58.1% (95% confidence interval [CI], 46.3%-72.9%) and 46.3% (95% CI, 34.2%-62.8%), respectively. Kaplan-Meier analysis with the log-rank test showed that gross total resection was superior to subtotal resection in prolonging survival (P = 0.047) and delayed time to recurrence (P < 0.01). Multivariate analysis confirmed gross total resection as an independent protective factor against relapse (odds ratio, 0.39; 95% CI, 0.17-0.89; P = 0.03). Age <50 years predicted longer overall survival (odds ratio, 0.16; 95% CI, 0.05-0.49; P < 0.01). Postoperative adjuvant therapy after gross total resection did not affect overall survival (P = 0.98) or progression-free survival (P = 0.93). Adjuvant therapy after subtotal resection favored improved overall survival (P = 0.052).
Clear cell ependymomas are particularly aggressive in those aged >50 years. Gross total resection remains the cornerstone of management. Postoperative adjuvant therapy is likely to be of survival benefit only after subtotal resection.
透明细胞室管膜瘤的生存结果了解甚少。本研究阐明了在遇到这种形态独特的肿瘤时手术和辅助治疗的作用。
对与透明细胞室管膜瘤相关的研究进行了系统检索。主要结果是无进展生存期和总生存期。预后变量为年龄、性别、肿瘤一致性、切除范围和术后辅助治疗。生成 Kaplan-Meier 生存曲线,并通过对数秩检验进行比较。构建多变量 Cox 回归模型,用 Schoenfeld 残差进行检验,并用于确定独立的预后因素。
在检索到的 384 篇文章中,纳入了 8 篇文章,共 77 例透明细胞室管膜瘤病例。5 年总生存率和无进展生存率分别为 58.1%(95%置信区间[CI]:46.3%-72.9%)和 46.3%(95%CI:34.2%-62.8%)。对数秩检验的 Kaplan-Meier 分析显示,大体全切除优于次全切除,可延长生存时间(P=0.047)和延迟复发时间(P<0.01)。多变量分析证实大体全切除是防止复发的独立保护因素(优势比,0.39;95%CI:0.17-0.89;P=0.03)。年龄<50 岁预测总生存期更长(优势比,0.16;95%CI:0.05-0.49;P<0.01)。大体全切除术后辅助治疗对总生存期(P=0.98)或无进展生存期(P=0.93)无影响。次全切除术后辅助治疗有利于改善总生存期(P=0.052)。
透明细胞室管膜瘤在年龄>50 岁的患者中更为侵袭性。大体全切除仍然是治疗的基石。术后辅助治疗可能仅在次全切除术后对生存有益。